Travis Steed
Stock Analyst at B of A Securities
(2.71)
# 1,901
Out of 5,114 analysts
91
Total ratings
45.07%
Success rate
6.41%
Average return
Main Sectors:
Stocks Rated by Travis Steed
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BBNX Beta Bionics | Maintains: Buy | $30 → $33 | $14.78 | +123.27% | 1 | Jan 5, 2026 | |
| PEN Penumbra | Maintains: Buy | $320 → $370 | $359.03 | +3.06% | 2 | Jan 5, 2026 | |
| BDX Becton, Dickinson and Company | Maintains: Neutral | $190 → $207 | $201.92 | +2.52% | 10 | Jan 5, 2026 | |
| CNMD CONMED | Maintains: Neutral | $65 → $52 | $38.69 | +34.40% | 5 | Dec 8, 2025 | |
| MASI Masimo | Initiates: Neutral | $162 | $137.67 | +17.67% | 1 | Nov 17, 2025 | |
| ABT Abbott Laboratories | Maintains: Buy | $133 → $150 | $106.05 | +41.44% | 5 | Mar 10, 2025 | |
| SOLV Solventum | Maintains: Neutral | $80 → $85 | $76.60 | +10.97% | 3 | Feb 26, 2025 | |
| EW Edwards Lifesciences | Upgrades: Buy | $82 → $90 | $81.86 | +9.94% | 4 | Dec 16, 2024 | |
| CBLL CeriBell | Initiates: Buy | $32 | $20.55 | +55.72% | 1 | Nov 5, 2024 | |
| BAX Baxter International | Maintains: Neutral | $42 → $45 | $19.61 | +129.47% | 5 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $480 → $45 | $5.03 | +795.52% | 1 | Oct 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $315 | $357.83 | -11.97% | 5 | Sep 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $365 → $295 | $258.20 | +14.25% | 3 | Aug 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $16 | $34.11 | -53.09% | 5 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $45 → $33 | $19.11 | +72.68% | 2 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $120 → $160 | $85.71 | +86.68% | 11 | May 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $300 → $315 | $522.04 | -39.66% | 2 | Apr 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $8 | $1.76 | +354.55% | 1 | Jan 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underperform | $25 | $10.20 | +145.10% | 1 | Jun 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $120 → $85 | $15.12 | +462.17% | 3 | Oct 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $125 | $73.36 | +70.39% | 7 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $145 | $100.79 | +43.86% | 1 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $51 | $93.79 | -45.62% | 9 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $59 → $54 | $10.88 | +396.32% | 2 | Nov 1, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22 | $66.31 | -66.82% | 1 | Jul 17, 2017 |
Beta Bionics
Jan 5, 2026
Maintains: Buy
Price Target: $30 → $33
Current: $14.78
Upside: +123.27%
Penumbra
Jan 5, 2026
Maintains: Buy
Price Target: $320 → $370
Current: $359.03
Upside: +3.06%
Becton, Dickinson and Company
Jan 5, 2026
Maintains: Neutral
Price Target: $190 → $207
Current: $201.92
Upside: +2.52%
CONMED
Dec 8, 2025
Maintains: Neutral
Price Target: $65 → $52
Current: $38.69
Upside: +34.40%
Masimo
Nov 17, 2025
Initiates: Neutral
Price Target: $162
Current: $137.67
Upside: +17.67%
Abbott Laboratories
Mar 10, 2025
Maintains: Buy
Price Target: $133 → $150
Current: $106.05
Upside: +41.44%
Solventum
Feb 26, 2025
Maintains: Neutral
Price Target: $80 → $85
Current: $76.60
Upside: +10.97%
Edwards Lifesciences
Dec 16, 2024
Upgrades: Buy
Price Target: $82 → $90
Current: $81.86
Upside: +9.94%
CeriBell
Nov 5, 2024
Initiates: Buy
Price Target: $32
Current: $20.55
Upside: +55.72%
Baxter International
Mar 5, 2024
Maintains: Neutral
Price Target: $42 → $45
Current: $19.61
Upside: +129.47%
Oct 13, 2023
Downgrades: Underperform
Price Target: $480 → $45
Current: $5.03
Upside: +795.52%
Sep 5, 2023
Upgrades: Buy
Price Target: $315
Current: $357.83
Upside: -11.97%
Aug 24, 2023
Maintains: Buy
Price Target: $365 → $295
Current: $258.20
Upside: +14.25%
Aug 22, 2023
Reiterates: Overweight
Price Target: $16
Current: $34.11
Upside: -53.09%
May 5, 2023
Downgrades: Underperform
Price Target: $45 → $33
Current: $19.11
Upside: +72.68%
May 3, 2023
Upgrades: Neutral
Price Target: $120 → $160
Current: $85.71
Upside: +86.68%
Apr 19, 2023
Maintains: Buy
Price Target: $300 → $315
Current: $522.04
Upside: -39.66%
Jan 3, 2023
Downgrades: Underperform
Price Target: $8
Current: $1.76
Upside: +354.55%
Jun 21, 2022
Initiates: Underperform
Price Target: $25
Current: $10.20
Upside: +145.10%
Oct 13, 2021
Maintains: Overweight
Price Target: $120 → $85
Current: $15.12
Upside: +462.17%
May 25, 2021
Initiates: Overweight
Price Target: $125
Current: $73.36
Upside: +70.39%
May 25, 2021
Initiates: Equal-Weight
Price Target: $145
Current: $100.79
Upside: +43.86%
May 25, 2021
Initiates: Overweight
Price Target: $51
Current: $93.79
Upside: -45.62%
Nov 1, 2018
Maintains: Neutral
Price Target: $59 → $54
Current: $10.88
Upside: +396.32%
Jul 17, 2017
Initiates: Overweight
Price Target: $22
Current: $66.31
Upside: -66.82%